ALEC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alector Inc (ALEC) is not a strong buy for a beginner, long-term investor at this time. While the company has promising technology and recent analyst upgrades, the financial performance is weak, insiders are selling, and the stock lacks immediate positive trading signals. Given the investor's impatience and preference for long-term investments, it is better to hold off for now and monitor the stock for better entry points.
The technical indicators show a mixed picture. The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 65.149, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its resistance level (R1: 2.615), which may limit further upside in the short term.
Analyst upgrades from Cantor Fitzgerald and BTIG, citing the potential of Alector's ABC platform in neurodegenerative disease treatment.
The company's focus on innovative brain-targeting therapies, which could position it as a leader in its field.
Insiders are selling heavily, with a 612.06% increase in selling activity over the last month.
Weak financial performance with a significant revenue drop (-88.50% YoY) and continued net losses.
No recent congress trading data or influential figure activity to support confidence in the stock.
In Q4 2025, revenue dropped significantly by -88.50% YoY to $6.24M. Net income improved to -$37.27M (up 1696.87% YoY), but the company remains unprofitable. EPS improved to -0.34, up 1600.00% YoY. Gross margin remained steady at 100%. Overall, the financials indicate weak growth and profitability.
Recent analyst upgrades from Cantor Fitzgerald and BTIG reflect optimism about Alector's ABC platform and its potential in neurodegenerative treatments. However, the $6 price target suggests limited upside from the current price of $2.54, and the upgrades are based on long-term potential rather than immediate performance.
